We use our own and third party cookies in order to improve our performance, and to obtain anonymous statistics about the use of the website. By continuing to browse, you authorize their use. In order to change the preferences and to obtain further information, please refer to our cookies policy.


Who we are

LETIPharma is the leading Spanish manufacturer in allergen immunotherapy, and aspires to become a world reference manufacturer in this field.

LETIPharma already possesses a significant market share in Portugal as well, and is making important contributions to the development of immunotherapy in various markets in Latin America. Since 2001, LETIPharma has been present in the German market—the first ranking world market in this speciality—where the widespread acceptance of our products allows us to view the future commercial development of this market with optimism.

Allergic pathology is clearly increasing in the industrialised world, and LETIPharma considers that immunotherapy will have an increasingly important role in the management of such diseases. The laboratory therefore reaffirms its commitment to this activity and maintains an ambitious research and technological investment program to maximise its competitive capacity in this field over the long term.